Linked Life Data

16086643

Source:http://linkedlifedata.com/resource/pubmed/id/16086643

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2005-8-9
pubmed:abstractText
Trastuzumab is a humanised monoclonal antibody that targets the extra cellular domain of human epidermal growth factor receptor-2 (HER-2), which is overexpressed in approximately 20% of human breast cancers. Clinical benefit has been shown in breast cancer patients with HER-2 amplification or overexpression when trastuzumab is used alone or in combination with chemotherapy. Docetaxel is one of the most potent chemotherapy agents in the treatment of patients with metastatic and early-stage breast cancer. The rationale for combining these two drugs is based not only on preclinical synergic data, but also on expanding clinical results. This article reviews the results of trials investigating this two-drug combination, as well as the triple combinations including docetaxel and trastuzumab with platinum salts. These combinations appear to be amongst the most active therapies for the treatment of patients with HER-2-positive breast cancer in metastatic and potentially adjuvant settings.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1744-7666
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1555-64
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:16086643-Animals, pubmed-meshheading:16086643-Antibodies, Monoclonal, pubmed-meshheading:16086643-Antibodies, Monoclonal, Humanized, pubmed-meshheading:16086643-Antineoplastic Agents, Phytogenic, pubmed-meshheading:16086643-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16086643-Breast Neoplasms, pubmed-meshheading:16086643-Chemotherapy, Adjuvant, pubmed-meshheading:16086643-Cisplatin, pubmed-meshheading:16086643-Drug Interactions, pubmed-meshheading:16086643-Drug Therapy, Combination, pubmed-meshheading:16086643-Female, pubmed-meshheading:16086643-Humans, pubmed-meshheading:16086643-Neoplasm Metastasis, pubmed-meshheading:16086643-Randomized Controlled Trials as Topic, pubmed-meshheading:16086643-Receptor, erbB-2, pubmed-meshheading:16086643-Taxoids, pubmed-meshheading:16086643-Treatment Outcome
pubmed:year
2005
pubmed:articleTitle
Docetaxel/trastuzumab combination therapy for the treatment of breast cancer.
pubmed:affiliation
Breast Cancer Research Institute, La Prandie, 24290 Valojoulx, France. jmnabholtz@hotmail.com ,
pubmed:publicationType
Journal Article, Review